Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
rosuvarina 10 mg filmovertrukne tabletter
centrient pharmaceuticals - rosuvastatin calcium - filmovertrukne tabletter - 10 mg
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
rosuvarina 20 mg filmovertrukne tabletter
centrient pharmaceuticals - rosuvastatin calcium - filmovertrukne tabletter - 20 mg
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
rosuvarina 40 mg filmovertrukne tabletter
centrient pharmaceuticals - rosuvastatin calcium - filmovertrukne tabletter - 40 mg
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
rosufy 10 mg filmovertrukne tabletter
centrient pharmaceuticals netherlands b.v. - rosuvastatin calcium - filmovertrukne tabletter - 10 mg
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
rosufy 20 mg filmovertrukne tabletter
centrient pharmaceuticals netherlands b.v. - rosuvastatin calcium - filmovertrukne tabletter - 20 mg
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
rosufy 40 mg filmovertrukne tabletter
centrient pharmaceuticals netherlands b.v. - rosuvastatin calcium - filmovertrukne tabletter - 40 mg
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
rosuvex 10 mg filmovertrukne tabletter
centrient pharmaceuticals netherlands b.v. - rosuvastatin calcium - filmovertrukne tabletter - 10 mg
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
rosuvex 20 mg filmovertrukne tabletter
centrient pharmaceuticals netherlands b.v. - rosuvastatin calcium - filmovertrukne tabletter - 20 mg
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
rosuvex 40 mg filmovertrukne tabletter
centrient pharmaceuticals netherlands b.v. - rosuvastatin calcium - filmovertrukne tabletter - 40 mg
Den Europæiske Union -
dansk -
EMA (European Medicines Agency)
sapropterin dipharma
dipharma arzneimittel gmbh - sapropterin dihydrochlorid - phenylketonurias - andre alimentary tract and metabolism produkter, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.